Mipharm SpA Report issue

For profit Phase 2 Phase 3
Founded: Milan Italy (1998)

Organization Overview

First Clinical Trial
2016
NCT03144947
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Mipharm SpA | Mipharm S.p.A.

Active Ingredients

Drugs in Phase 3 Trials (1)

nivolumab (opdivo) (1 trial)

Drugs in Phase 2 Trials (3)

cabozantinib (cometriq) (1 trial)

paclitaxel (taxol) (1 trial)

trastuzumab (herceptin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4